[{"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-001", "question": "A 45-year-old male presents with syncope. ECG shows sinus rhythm with first-degree AV block and a right bundle branch block. Echocardiogram reveals a left ventricular ejection fraction (LVEF) of 42% with mild LV dilation. Genetic testing confirms a pathogenic variant in the LMNA gene (Lamin A/C). He has no history of sustained ventricular tachycardia. Which of the following is the most appropriate management?", "options": ["Implantation of a dual-chamber pacemaker", "Implantation of an implantable cardioverter-defibrillator (ICD)", "Implantation of an implantable loop recorder", "Initiation of Amiodarone", "Initiation of Metoprolol and reassessment of LVEF in 3 months"], "answer": "B", "answer_index": 1, "explanation": "Lamin A/C (LMNA) cardiomyopathy carries a disproportionately high risk of malignant ventricular arrhythmias and sudden cardiac death, often independent of the degree of LV dysfunction. Current guidelines recommend ICD implantation for patients with an LMNA mutation and risk factors such as AV block, male sex, or non-missense mutations, even if the LVEF is >35%. A pacemaker alone addresses the conduction disease but leaves the patient unprotected against the high risk of fatal ventricular arrhythmias.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the clinical presentation and the significance of the LMNA gene mutation.\n\nThe patient presents with:\n- Syncope\n- First-degree AV block and RBBB on ECG\n- Reduced LVEF (42%) with mild LV dilation\n- Confirmed pathogenic LMNA gene mutation\n- No history of sustained ventricular tachycardia\n\nLMNA mutations are associated with laminopathies that can cause dilated cardiomyopathy with conduction system disease. These patients have a high risk of sudden cardiac death even with moderate LV dysfunction.\n\nKey considerations:\n- The conduction abnormalities (first-degree AV block and RBBB) suggest progressive conduction disease\n- The reduced LVEF (42%) indicates cardiomyopathy\n- Syncope in this context is concerning for arrhythmic events\n- LMNA mutations carry a high risk of malignant ventricular arrhythmias\n\nGiven these factors, particularly the LMNA mutation with syncope and reduced LVEF, this patient has a high risk of sudden cardiac death that warrants primary prevention with an ICD, even without documented sustained ventricular tachycardia.\n\nA pacemaker alone would be insufficient as it wouldn't protect against ventricular arrhythmias. A loop recorder would only document arrhythmias but not treat them. Amiodarone or metoprolol alone would not provide adequate protection against sudden death in this high-risk genetic cardiomyopathy.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-002", "question": "A 68-year-old male presents with a 3-week history of brief, involuntary jerking movements of his right face and arm, occurring up to 40 times per day. He remains conscious during these events. Interictal EEG and brain MRI are unremarkable. He is beginning to show signs of short-term memory impairment. Which of the following is the most appropriate initial treatment?", "options": ["Levetiracetam", "Carbamazepine", "Intravenous Methylprednisolone", "Tissue Plasminogen Activator (tPA)", "Haloperidol"], "answer": "C", "answer_index": 2, "explanation": "The clinical presentation is classic for faciobrachial dystonic seizures (FBDS), which are pathognomonic for Anti-LGI1 encephalitis (a form of limbic encephalitis). These seizures are characteristically resistant to standard anti-epileptic drugs but respond dramatically to immunotherapy (steroids, IVIG). Early recognition and treatment with immunotherapy are crucial to prevent the progression to severe cognitive impairment and full-blown limbic encephalitis.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "I need to analyze this case of a 68-year-old male with brief, involuntary jerking movements of the right face and arm.\n\nThe key features are:\n- Brief, involuntary jerking movements (up to 40 times daily)\n- Right-sided involvement (face and arm)\n- Patient remains conscious during events\n- Normal interictal EEG and brain MRI\n- Developing short-term memory impairment\n\nThese symptoms are consistent with focal seizures (specifically, focal motor seizures), given the brief, stereotyped movements with preserved consciousness. The right-sided involvement suggests a left hemisphere focus.\n\nFor initial treatment of focal seizures:\n- Levetiracetam is a broad-spectrum antiepileptic drug with good efficacy for focal seizures, favorable side effect profile, and minimal drug interactions\n- Carbamazepine is effective for focal seizures but has more side effects and drug interactions\n- Methylprednisolone would be used if an inflammatory/autoimmune etiology was confirmed\n- tPA is for acute ischemic stroke, not seizures\n- Haloperidol is an antipsychotic, not indicated for seizures\n\nGiven the patient's age and developing memory issues, levetiracetam would be preferred over carbamazepine due to fewer cognitive side effects and drug interactions.\n\nThe answer is (A)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-003", "question": "A 55-year-old female is admitted to the ICU with sepsis and severe malnutrition. She has a history of chronic back pain managed with acetaminophen. Arterial blood gas shows pH 7.26, pCO2 28 mmHg, HCO3 12 mEq/L. Serum chemistry shows Na 140, Cl 104, BUN 18, Cr 0.8. Lactate is 1.1 mmol/L. Serum ketones are negative. Measured serum osmolality is 295 mOsm/kg (calculated 290). Which of the following is the most likely etiology of her metabolic acidosis?", "options": ["Methanol intoxication", "D-lactic acidosis", "Pyroglutamic acidosis (5-oxoproline accumulation)", "Propylene glycol toxicity", "Salicylate toxicity"], "answer": "C", "answer_index": 2, "explanation": "The patient has a high anion gap metabolic acidosis (AG = 24) with a normal lactate, no ketones, normal renal function, and a normal osmol gap (ruling out toxic alcohols like methanol or propylene glycol). The combination of chronic acetaminophen use, sepsis, and malnutrition leads to glutathione depletion, causing a disruption in the gamma-glutamyl cycle and accumulation of 5-oxoproline (pyroglutamic acid). This is an under-recognized cause of high anion gap acidosis in this specific patient population.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To determine the etiology of this patient's metabolic acidosis, I'll analyze the available information:\n\nThe patient has:\n- Metabolic acidosis (pH 7.26, low HCO3 12 mEq/L)\n- Respiratory compensation (low pCO2 28 mmHg)\n- Normal anion gap = Na - (Cl + HCO3) = 140 - (104 + 12) = 24 mEq/L (elevated)\n- Normal lactate (1.1 mmol/L)\n- Negative ketones\n- Small osmolar gap (5 mOsm/kg)\n- History of chronic acetaminophen use\n- Severe malnutrition\n\nLooking at each option:\nA. Methanol intoxication - Would cause a large osmolar gap and visual symptoms\nB. D-lactic acidosis - Possible with malabsorption but typically requires short bowel syndrome\nC. Pyroglutamic acidosis - Associated with chronic acetaminophen use, especially in malnourished patients with glutathione depletion\nD. Propylene glycol toxicity - Would cause a larger osmolar gap\nE. Salicylate toxicity - No history of salicylate use, would have respiratory alkalosis\n\nThe patient's chronic acetaminophen use combined with severe malnutrition creates conditions for glutathione depletion, leading to accumulation of 5-oxoproline (pyroglutamic acid). This explains the high anion gap metabolic acidosis without elevated lactate or ketones.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-004", "question": "A 34-year-old male presents with progressive dyspnea. He has a BMI of 17 kg/m2. Chest radiography shows apical pleural thickening. High-resolution CT demonstrates upper-lobe predominant subpleural fibrosis and a flattened chest configuration ('platythorax'). He has no history of asbestos exposure or connective tissue disease. Which of the following is the most likely diagnosis?", "options": ["Idiopathic Pulmonary Fibrosis (IPF)", "Pleuroparenchymal Fibroelastosis (PPFE)", "Chronic Hypersensitivity Pneumonitis", "Lymphangioleiomyomatosis (LAM)", "Pulmonary Alveolar Proteinosis"], "answer": "B", "answer_index": 1, "explanation": "Pleuroparenchymal Fibroelastosis (PPFE) is a rare idiopathic interstitial pneumonia characterized by fibrosis of the visceral pleura and subpleural lung parenchyma, predominantly in the upper lobes. The radiographic hallmark is the 'platythorax' (flattening of the chest cage) due to fibrosis progression. This contrasts with IPF (lower lobe predominant) and Hypersensitivity Pneumonitis (mosaic attenuation, centrilobular nodules).", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most likely diagnosis, I'll analyze the key clinical and radiographic findings presented in this case.\n\nKey findings:\n- 34-year-old male\n- Progressive dyspnea\n- Low BMI (17 kg/mÂ²)\n- Apical pleural thickening on chest X-ray\n- Upper-lobe predominant subpleural fibrosis on HRCT\n- Flattened chest configuration (\"platythorax\")\n- No asbestos exposure or connective tissue disease\n\nAnalysis of options:\nA. Idiopathic Pulmonary Fibrosis (IPF): Typically affects older adults (>60 years), shows lower lobe predominant fibrosis with honeycomb pattern, and doesn't cause platythorax.\n\nB. Pleuroparenchymal Fibroelastosis (PPFE): Characterized by upper lobe predominant subpleural fibrosis, pleural thickening, and often associated with low BMI and flattened chest configuration. These findings match our patient perfectly.\n\nC. Chronic Hypersensitivity Pneumonitis: Usually shows mid to upper lung predominance but with centrilobular nodules and ground-glass opacities rather than pleural thickening. Platythorax is not a typical feature.\n\nD. Lymphangioleiomyomatosis (LAM): Predominantly affects females, with diffuse thin-walled cysts throughout both lungs, not fibrosis.\n\nE. Pulmonary Alveolar Proteinosis: Presents with ground-glass opacities in a crazy-paving pattern, not fibrosis or pleural thickening.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-005", "question": "A 24-year-old African American male presents with cyanosis and shortness of breath after taking dapsone for a skin lesion. Pulse oximetry reads 85% and does not improve with supplemental oxygen. Arterial blood gas shows a normal PaO2 but methemoglobin level is 18%. He has a known history of hemolysis after ingesting fava beans. Which of the following is the most appropriate treatment?", "options": ["Methylene Blue 1 mg/kg IV", "Ascorbic Acid (Vitamin C) IV", "Hydroxocobalamin IV", "Hyperbaric Oxygen Therapy", "Sodium Thiosulfate IV"], "answer": "B", "answer_index": 1, "explanation": "The patient has methemoglobinemia precipitated by dapsone. However, his history of hemolysis with fava beans strongly suggests Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency. Methylene blue is contraindicated in G6PD deficiency because it requires NADPH (generated by G6PD) to reduce methemoglobin; without G6PD, methylene blue is ineffective and can induce severe hemolysis. Ascorbic acid (Vitamin C) or exchange transfusion is the appropriate management.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the patient's presentation and medical history.\n\nThe patient has:\n- Methemoglobinemia (18% level) induced by dapsone\n- History of hemolysis with fava beans (suggesting G6PD deficiency)\n- Cyanosis and shortness of breath not responsive to oxygen\n\nMethemoglobinemia is typically treated with Methylene Blue, which acts as a cofactor for NADPH-methemoglobin reductase to convert methemoglobin back to hemoglobin. However, Methylene Blue is contraindicated in G6PD deficiency (which this patient likely has based on his fava bean reaction) because it can worsen hemolysis.\n\nFor patients with G6PD deficiency and methemoglobinemia, Ascorbic Acid (Vitamin C) is the preferred treatment. It works through a slower, alternative reduction pathway that doesn't require G6PD.\n\nHydroxocobalamin is used for cyanide poisoning, not methemoglobinemia.\nHyperbaric oxygen therapy isn't effective for methemoglobinemia.\nSodium thiosulfate is used for cyanide poisoning, not methemoglobinemia.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-006", "question": "A 14-year-old boy with a history of exercise-induced syncope is diagnosed with Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) confirmed by an RyR2 mutation. He is compliant with high-dose Nadolol. A repeat exercise stress test shows a reduction in arrhythmia burden, but he still develops runs of bidirectional ventricular tachycardia at peak exertion. Which of the following is the best next step in management?", "options": ["Switch Nadolol to Metoprolol Succinate", "Add Flecainide", "Perform Radiofrequency Ablation of the ventricular focus", "Implant a dual-chamber pacemaker", "Add Verapamil"], "answer": "B", "answer_index": 1, "explanation": "In patients with CPVT who have breakthrough arrhythmias despite optimal beta-blocker therapy (preferably Nadolol or Propranolol), the addition of Flecainide is the guideline-recommended next step. Flecainide has a direct blocking effect on the cardiac ryanodine receptor (RyR2), addressing the underlying mechanism. Radiofrequency ablation is generally ineffective due to the polymorphic/multifocal nature of the arrhythmia.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To answer this question, I need to consider the management of Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT) in a patient who is still experiencing arrhythmias despite beta-blocker therapy.\n\nCPVT is characterized by adrenergically-mediated polymorphic or bidirectional ventricular tachycardia, typically triggered by exercise or emotional stress. The RyR2 mutation affects the cardiac ryanodine receptor, leading to abnormal calcium handling in cardiac cells.\n\nThe patient is already on high-dose Nadolol (a non-selective beta-blocker), which is first-line therapy for CPVT. Despite compliance, he still has breakthrough arrhythmias during peak exertion.\n\nLet's evaluate each option:\n\nA. Switching from Nadolol to Metoprolol Succinate would not be beneficial, as Nadolol is actually preferred in CPVT due to its longer half-life and non-selective beta-blockade.\n\nB. Flecainide is a class IC antiarrhythmic that has shown efficacy as an add-on therapy in CPVT by directly inhibiting RyR2 channels, reducing calcium release, and suppressing triggered activity.\n\nC. Radiofrequency ablation is generally not effective for CPVT as it's not a focal arrhythmia but rather a generalized channelopathy affecting the entire myocardium.\n\nD. A dual-chamber pacemaker alone would not address the underlying pathophysiology of CPVT.\n\nE. While Verapamil can affect calcium handling, it is not a standard add-on therapy for CPVT and has less evidence than Flecainide.\n\nBased on current guidelines and evidence, adding Flecainide to beta-blocker therapy is the recommended next step for patients with CPVT who continue to have arrhythmias despite optimal beta-blocker therapy.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-007", "question": "A 26-year-old female with a history of sensorineural hearing loss and short stature presents with acute onset aphasia and right-sided hemiparesis. MRI shows a T2-hyperintense lesion in the left temporal lobe that does not conform to a vascular territory. Serum lactate is elevated. Which of the following agents is indicated for the acute management of this condition?", "options": ["Intravenous Tissue Plasminogen Activator (tPA)", "Intravenous Arginine", "Intravenous Heparin", "High-dose Aspirin", "Plasma Exchange"], "answer": "B", "answer_index": 1, "explanation": "The clinical picture (stroke-like episode not respecting vascular territories, hearing loss, elevated lactate) is classic for MELAS (Mitochondrial Encephalomyopathy, Lactic Acidosis, and Stroke-like episodes). The stroke-like episodes are due to metabolic failure and microvascular angiopathy (nitric oxide deficiency), not thrombotic occlusion. Intravenous Arginine is the recommended acute treatment to improve nitric oxide availability and cerebral blood flow. tPA is not indicated and could be harmful.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "I need to analyze this case presentation carefully:\n\nThe patient has:\n- Sensorineural hearing loss and short stature (suggesting a mitochondrial disorder)\n- Acute stroke-like symptoms (aphasia and hemiparesis)\n- MRI showing a lesion that doesn't follow vascular territories\n- Elevated serum lactate\n\nThese findings are consistent with MELAS syndrome (Mitochondrial Encephalopathy, Lactic Acidosis, and Stroke-like episodes), which is a mitochondrial disorder.\n\nFor acute management of stroke-like episodes in MELAS:\n- tPA (A) is not indicated as this is not a true ischemic stroke\n- Arginine (B) is the recommended treatment for acute stroke-like episodes in MELAS\n- Heparin (C) is for anticoagulation, not appropriate here\n- Aspirin (D) is for antiplatelet therapy, not appropriate here\n- Plasma exchange (E) is not a standard treatment for MELAS\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-008", "question": "A 32-year-old female is evaluated for palpitations. Labs reveal a TSH of 7.2 mIU/L (High) and Free T4 of 2.9 ng/dL (High). An MRI of the pituitary shows a 5mm hypoenhancing lesion. Sex Hormone Binding Globulin (SHBG) levels are elevated. Which of the following is the most likely diagnosis?", "options": ["Resistance to Thyroid Hormone (RTH) beta", "TSH-secreting pituitary adenoma (TSHoma)", "Graves' disease", "Familial Dysalbuminemic Hyperthyroxinemia", "Heterophile antibody interference"], "answer": "B", "answer_index": 1, "explanation": "Both RTH and TSHoma present with inappropriate TSH secretion (high T4, non-suppressed TSH). The key differentiator is the peripheral tissue response. In TSHoma, peripheral tissues (like the liver) are sensitive to the high thyroid hormone levels, resulting in elevated markers of thyroid action such as Sex Hormone Binding Globulin (SHBG). In RTH, the peripheral tissues are resistant, so SHBG levels are typically normal. The pituitary lesion supports TSHoma, but incidentalomas are common; the metabolic profile (high SHBG) confirms the diagnosis.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "To determine the most likely diagnosis, I'll analyze the key findings in this case:\n\n1. Elevated TSH (7.2 mIU/L) AND elevated Free T4 (2.9 ng/dL)\n2. 5mm pituitary lesion on MRI\n3. Elevated SHBG levels\n4. Patient presenting with palpitations\n\nThis combination of high TSH with high Free T4 is unusual and narrows our differential:\n\n- TSH-secreting pituitary adenoma (TSHoma): Characterized by inappropriate TSH secretion causing hyperthyroidism. The pituitary lesion, elevated SHBG (which increases with hyperthyroidism), and clinical hyperthyroidism (palpitations) strongly support this diagnosis.\n\n- Resistance to Thyroid Hormone beta: Would show elevated T3/T4 with normal/elevated TSH, but typically doesn't present with clear hyperthyroid symptoms like palpitations.\n\n- Graves' disease: Would show suppressed (low) TSH with high T4, not elevated TSH.\n\n- Familial Dysalbuminemic Hyperthyroxinemia: Causes falsely elevated total T4 but usually normal free T4 and normal TSH.\n\n- Heterophile antibody interference: Could cause laboratory artifacts but wouldn't explain the pituitary lesion.\n\nThe combination of high TSH, high Free T4, pituitary lesion, elevated SHBG, and hyperthyroid symptoms is most consistent with a TSH-secreting pituitary adenoma.\n\nThe answer is (B)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-009", "question": "A 48-year-old male who works as a tool grinder presents with chronic dry cough and dyspnea. Bronchoalveolar lavage (BAL) reveals multinucleated giant cells that appear to be engulfing other cells ('cannibalistic' giant cells). Which of the following exposures is most likely responsible for this finding?", "options": ["Silica", "Asbestos", "Cobalt", "Beryllium", "Coal dust"], "answer": "C", "answer_index": 2, "explanation": "The presence of 'cannibalistic' multinucleated giant cells in BAL or biopsy is pathognomonic for Hard Metal Lung Disease (Giant Cell Interstitial Pneumonia). This is caused by exposure to Cobalt, often in the form of tungsten carbide alloy used in tool grinding, diamond polishing, or saw sharpening. Beryllium causes granulomas similar to sarcoidosis, not GIP.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "To answer this question, I need to identify which occupational exposure is associated with multinucleated giant cells that appear \"cannibalistic\" in bronchoalveolar lavage.\n\nThe patient works as a tool grinder, which is relevant for occupational exposures.\n\nLet me analyze each option:\n\nA. Silica - Silicosis is characterized by nodular fibrosis and silicotic nodules with birefringent particles. While multinucleated giant cells can be present, the \"cannibalistic\" appearance is not typical.\n\nB. Asbestos - Asbestosis presents with ferruginous bodies and interstitial fibrosis. Multinucleated giant cells are not a prominent feature.\n\nC. Cobalt - Hard metal lung disease (from tungsten carbide/cobalt exposure) is characterized by giant cell interstitial pneumonitis with cannibalistic multinucleated giant cells. Tool grinders often work with hard metal tools containing cobalt.\n\nD. Beryllium - Chronic beryllium disease shows non-caseating granulomas similar to sarcoidosis, but the \"cannibalistic\" giant cell appearance is not typical.\n\nE. Coal dust - Coal worker's pneumoconiosis shows coal macules and progressive massive fibrosis, but not typically cannibalistic giant cells.\n\nThe description of \"cannibalistic\" giant cells is most consistent with hard metal lung disease from cobalt exposure, which can occur in tool grinders.\n\nThe answer is (C)"}, {"quiz_id": "20251129T125426901Z_gemini-3-pro-preview_seed123", "question_id": "20251129T125426901Z_gemini-3-pro-preview_seed123-010", "question": "A 52-year-old male presents to the ED 2 hours after ingesting a massive overdose of sustained-release Verapamil. He is hypotensive (BP 60/40 mmHg) and bradycardic (HR 38 bpm). He remains hypotensive despite 3 liters of crystalloid, IV Calcium Gluconate, and IV Glucagon. Which of the following is the most appropriate next therapeutic intervention?", "options": ["High-dose Insulin Euglycemia therapy", "Transvenous Pacing", "Hemodialysis", "IV Amiodarone", "IV Lipid Emulsion (20%)"], "answer": "A", "answer_index": 0, "explanation": "High-dose Insulin Euglycemia (HIE) is the recommended therapy for severe calcium channel blocker toxicity refractory to initial measures (fluids, calcium). Insulin has a positive inotropic effect and improves myocardial glucose utilization in the stressed heart. While lipid emulsion is a salvage therapy, HIE has stronger evidence as a first-line pharmacologic support after calcium/fluids. Transvenous pacing often fails to capture or improve cardiac output in severe CCB poisoning due to global myocardial depression.", "generator_model": "gemini-3-pro-preview", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "For a patient with severe verapamil overdose presenting with refractory hypotension and bradycardia despite standard treatments (fluids, calcium, glucagon), I need to determine the most effective next intervention.\n\nVerapamil is a calcium channel blocker that causes hypotension and bradycardia in overdose by blocking calcium influx into cardiac and vascular smooth muscle cells.\n\nLet me analyze each option:\n\nA. High-dose Insulin Euglycemia therapy - This is specifically recommended for calcium channel blocker overdoses. It improves cardiac contractility and peripheral vascular resistance when other therapies fail.\n\nB. Transvenous Pacing - While this might address bradycardia, it won't improve the hypotension caused by peripheral vasodilation and decreased contractility.\n\nC. Hemodialysis - Not effective for verapamil as it has a large volume of distribution and high protein binding.\n\nD. IV Amiodarone - Contraindicated as it would worsen bradycardia and hypotension.\n\nE. IV Lipid Emulsion - While sometimes used for lipophilic drug overdoses, it's not first-line for calcium channel blocker overdoses after the initial treatments have failed.\n\nHigh-dose insulin euglycemia therapy has shown significant efficacy in calcium channel blocker overdoses refractory to standard treatments.\n\nThe answer is (A)"}]